105
Views
15
CrossRef citations to date
0
Altmetric
Review

Emerging treatment options for short bowel syndrome: potential role of teduglutide

, &
Pages 189-196 | Published online: 19 Aug 2011

Figures & data

Figure 1 Proglucagon contains three homologous hormonal sequences, glucagon/GLP-1/GLP-2, and is separated by intervening peptides IP1/IP2. Proglucagon is processed differentially in pancreas, intestine, and CNS.

Abbreviations: CNS, central nervous system; GLP, glucagon-like peptide; GRPP, glicentin-related polypeptide; IP, intervening peptide; MPGF, major proglucagon fragment.
Figure 1 Proglucagon contains three homologous hormonal sequences, glucagon/GLP-1/GLP-2, and is separated by intervening peptides IP1/IP2. Proglucagon is processed differentially in pancreas, intestine, and CNS.

Figure 2 Effect of GLP-2 on murine small intestine. Histological appearance of small intestine epithelium from control (A) and GLP-2-injected (10 days) (B) mice. Reproduced with permission from Drucker et al.Citation11

© Copyright 1996 National Academy of Sciences, USA.

Abbreviation: GLP, glucagon-like peptide.
Figure 2 Effect of GLP-2 on murine small intestine. Histological appearance of small intestine epithelium from control (A) and GLP-2-injected (10 days) (B) mice. Reproduced with permission from Drucker et al.Citation11© Copyright 1996 National Academy of Sciences, USA.

Figure 3 Proposed model for the indirect mechanisms of GLP-2 action in the intestine. Expression of the GLP-2R in intestinal endocrine cells (A), intestinal SEMFs (B), and enteric neurons (C) suggests that GLP-2 acts indirectly to produce its diverse actions in the intestine. IGF-I is critical for the ability of GLP-2 to induce intestinal growth and activate crypt cell proliferation. GLP-2-mediated enteric neuronal signaling enhances intestinal blood flow through a mechanism involving NO production and has anti-inflammatory actions through VIP.

Used with permission from Dubé et al, American Journal of Physiology – Endocrinology and Metabolism, Vol 293; E460–E465, 2007.Citation22

Abbreviations: GLP-2, glucagon-like peptide-2; GLP-2R, glucagon-like peptide-2 receptor; IGF, insulin-like growth factor; NO, nitric oxide; SEMF, subepithelial myofibroblast; VIP, vasoactive intestinal polypeptide.
Figure 3 Proposed model for the indirect mechanisms of GLP-2 action in the intestine. Expression of the GLP-2R in intestinal endocrine cells (A), intestinal SEMFs (B), and enteric neurons (C) suggests that GLP-2 acts indirectly to produce its diverse actions in the intestine. IGF-I is critical for the ability of GLP-2 to induce intestinal growth and activate crypt cell proliferation. GLP-2-mediated enteric neuronal signaling enhances intestinal blood flow through a mechanism involving NO production and has anti-inflammatory actions through VIP.Used with permission from Dubé et al, American Journal of Physiology – Endocrinology and Metabolism, Vol 293; E460–E465, 2007.Citation22